Tina Liedtky: Thermo Fisher Scientific Launches New Test to Help Guide Tacrolimus Dosing
Tina Liedtky, President of the Transplant Diagnostics Division at Thermo Fisher Scientific, shared a post on LinkedIn:
“In transplant medicine, every patient is unique. And healthcare teams need tools that enable them to provide personalized care.
To this end, I am excited to share that, today, Thermo Fisher Scientific launched a new laboratory developed test to help inform clinicians on dosing tacrolimus, a commonly prescribed immunosuppressive drug that can help lower the risk of transplant rejection.
The right tacrolimus dose will vary from patient to patient.
With the new TacroType Pharmacogenetic Test, clinicians can better understand how their patient is likely to metabolize tacrolimus and respond to certain therapies.
This pharmacogenetic information is invaluable.
Learn more about what the new TacroType Pharmacogenetic Test means for patient care by reading the press release.”
Stay updated with Hemostasis Today.
-
Sep 5, 2026, 19:20Yubrine Moraa Gachemba: BETULA Adds New Evidence for Catheter-Directed Thrombolysis in PE
-
Sep 5, 2026, 19:18John R. Mehall: The Importance of Anticoagulation Management in ECMO
-
Sep 5, 2026, 19:16Thirunavukkarasu Angappan: Why Hemophilia B Still Needs Both Plasma-Derived and Recombinant Factor IX
-
Sep 5, 2026, 19:15Michelle Leona Cecil: Comprehensive Hemophilia Care Doesn’t Begin and End With One Appointment
-
Sep 5, 2026, 19:13Amparo Santamaria: Stem Cells and Hematology – Unlocking a New Frontier in Ovarian Regeneration
-
Sep 5, 2026, 19:10Strengthening the Public Health System for Blood Disorders – Hemophilia Federation of America
-
Sep 5, 2026, 19:08Deidra D. Harris: Supporting Hemophilia of Georgia and the Bleeding Disorders Community
-
Sep 5, 2026, 19:06Katherine Blackwell: Blessed to Have the Opportunity to Speak at the Hemophilia of Indiana Annual Meeting
-
Sep 5, 2026, 19:04Christy V.: What You Need to Know about GI Bleeding and Hemophilia